Market Pulse Archives

Oct. 19, 2020, 10:49 a.m. EDT

Compass Therapeutics files to go public on the Nasdaq

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Renaissance IPO ETF (IPO)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Compass Therapeutics Inc., the Massachusetts-based biopharmaceutical company focused on cancer treatments, has filed to go public. The company, founded in 2014, has not yet determined the number of shares it expects to offer in its initial public offering, or what the IPO is expected to price at. The company expects its stock to list on the Nasdaq under the ticker symbol "CMPX" when it goes public. Citigroup, Credit Suisse and Stifel are the joint book-running managers. In the six months ended June 30, the company recorded a net loss of $12.0 million on no revenue, after a loss of $19.6 million on no revenue in the same period a year ago. The company is looking to go public at a time of relatively good investor demand for IPOs, as the Renaissance IPO ETF /zigman2/quotes/207665280/composite IPO +1.35% has rallied 31.1% over the past three months, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.56% has gained 7.9%.

/zigman2/quotes/207665280/composite
US : U.S.: NYSE Arca
$ 58.71
+0.78 +1.35%
Volume: 322,341
Nov. 23, 2020 4:00p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,577.59
+20.05 +0.56%
Volume: 2.51B
Nov. 23, 2020 5:02p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.